Irritable Bowel Syndrome
Conditions
Brief summary
The goal of this clinical trial is to explore the pathophysiological effects of the persistently colonized microbiome in irritable bowel syndrome (IBS) patients. The main questions it aims to answer are: Question 1: the microbiome difference of the biofilm between IBS and healthy patients. Question 2: the metabolic product patterns between IBS and healthy patients. Participants will need to take a colonoscopy examination, two gut mucosal biopsy samples will be collected during the examination. Researchers will compare the IBS and healthy control groups to see if there was the disease-specific pattern in the microbiome and metabolic product of the biofilm.
Interventions
DIAGNOSTIC_TESTcolonoscopy
colonoscopy
Sponsors
Jinhua Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* IBS patients with IV type; no abdominal surgery;
Exclusion criteria
* age \<18 y; * major disease; * alcoholic addicted; * antibiotic use in past 3 months; * severe gastrointestinal disease * severe cardiac disease; * pregnant; * ICU in past 1 year; * vegeterian; * immune disease (SLE etc.) * mental disease;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| mirobiome difference of the fecal between IBS and health controls | Fecal samples will be collected immediately before the colonoscopy (T1) and 7 days after the colonoscopy test (T2) | 16S rDNA sequencing will be applied in fecal samples all the above participants |
| Metabolic changes between IBS and Healthy controls | 1 day biopsy will be collected during the colonoscopy test | mucosal biopsy will be collected during the colonoscopy in each patients |
Countries
China
Contacts
Primary ContactWEI WEI
Outcome results
None listed